Unproven adoption of 3D tissue models
Commercial demand may develop slowly if customers do not adopt NAM methods at scale.
- Scope
- Services platform and internal research programs
- Materiality
- high
VivoSim Labs, INC.
VivoSim Labs, Inc. is a U.S.-based pharmaceutical and biotechnology services company focused on 3D human tissue models of liver and intestine. Through its subsidiaries, it combines toxicology testing, drug-response research, and related intellectual property licensing around non-animal new approach methodologies (NAMs).
−8 604,6 %
100,0 %
−10 567,2 %
−9,0 %
2.38
| % | |
|---|---|
| 3D tissue toxicology services | 55% Testing of drugs and drug candidates in liver and intestinal human tissue models. |
| Investigational and mechanism studies | 20% Custom research services using complex human tissue models to study drug effects and biology. |
| IP licensing and royalties | 20% Royalties and licensing income from intellectual property and related agreements. |
| Human cell products | 5% Cell-based products sold through the former Mosaic Cell Sciences business. |
Customers are primarily pharmaceutical and biotechnology companies that need human-relevant data to evaluate drug...
- Pharmaceutical companiesprimary
Buy toxicology and mechanism studies to de-risk drug candidates before clinical development.
- Biotechnology companiesprimary
Use 3D tissue models and custom studies to support discovery and translational research.
- Research collaboratorssecondary
Partner on exploratory studies, validation work, and disease-model applications.
- Life-science product customerssecondary
Purchase human cell-based products for R&D and laboratory use.
- Licensees and royalty payorssecondary
Generate royalty revenue through use of licensed intellectual property.
VivoSim Labs is headquartered in San Diego, California and operates as a U.S.-based company...
- •Headquartered in San Diego, California
- •U.S.-based corporate and scientific operations
- •Nasdaq Capital Market listing in the United States
- •Customer and licensing relationships may be international
- •Human cell sourcing depends on third-party suppliers
The company is repositioning around 3D human tissue models, NAM-based toxicology services, and related intellectual...
01
Grow NAM-based toxicology servicesshort-term
Human tissue models can provide more relevant drug-safety insights than traditional approaches.
02
Deepen partner and collaboration networkmedium-term
External relationships are needed to commercialize services and broaden scientific applications.
03
Monetize intellectual property and legacy assetsmedium-term
Licensing and royalties can support the business while the services platform scales.
The business depends on unproven commercial adoption of 3D tissue models, continued access to human cells, and the...
Human cell supply constraints
The company relies on third-party suppliers for qualified human cells used in tissue models.
- Scope
- Liver and intestine tissue activities
- Materiality
- high
Financing and liquidity pressure
The company requires additional capital to fund operations and development activities.
- Scope
- Corporate overhead and ongoing R&D
- Materiality
- high
Partnering and collaboration risk
The business model depends on strategic relationships to commercialize services and IP.
- Scope
- Pharma, biotech, university, hospital, and government partners
- Materiality
- high
Talent retention and recruitment
Scientific and operational execution depends on specialized employees and contractors.
- Scope
- R&D, service delivery, and business development
- Materiality
- medium
Revenue recognition
Affects timing and volatility of reported revenue
Sales-based royalties
Can create lumpy revenue recognition
Stock-based compensation
Affects operating expense and reported losses
Contingent milestone consideration
Could affect future cash receipts and accounting judgments
: 29.4.2026